Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ebunoluwa A. Adejuyigbe is active.

Publication


Featured researches published by Ebunoluwa A. Adejuyigbe.


The Lancet | 2015

Simplified antibiotic regimens compared with injectable procaine benzylpenicillin plus gentamicin for treatment of neonates and young infants with clinical signs of possible serious bacterial infection when referral is not possible: a randomised, open-label, equivalence trial

Antoinette Tshefu; Adrien Lokangaka; Serge Ngaima; Cyril Engmann; Fabian Esamai; Peter Gisore; Adejumoke I. Ayede; Adegoke Gbadegesin Falade; Ebunoluwa A. Adejuyigbe; Chineme Henry Anyabolu; Robinson D. Wammanda; Clara Ejembi; William N. Ogala; Lu Gram; Simon Cousens

BACKGROUND WHO recommends hospital-based treatment for young infants aged 0-59 days with clinical signs of possible serious bacterial infection, but most families in resource-poor settings cannot accept referral. We aimed to assess whether use of simplified antibiotic regimens to treat young infants with clinical signs of severe infection was as efficacious as an injectable procaine benzylpenicillin-gentamicin combination for 7 days for situations in which hospital referral was not possible. METHODS In a multisite open-label equivalence trial in DR Congo, Kenya, and Nigeria, community health workers visited all newborn babies at home, identifying and referring unwell young infants to a study nurse. We stratified young infants with clinical signs of severe infection whose parents did not accept referral to hospital by age (0-6 days and 7-59 days), and randomly assigned each individual within these strata to receive one of the four treatment regimens. Randomisation was stratified by age group of infants. An age-stratified randomisation scheme with block size of eight was computer-generated off-site at WHO. The outcome assessor was masked. We randomly allocated infants to receive injectable procaine benzylpenicillin-gentamicin for 7 days (group A, reference group); injectable gentamicin and oral amoxicillin for 7 days (group B); injectable procaine benzylpenicillin-gentamicin for 2 days, then oral amoxicillin for 5 days (group C); or injectable gentamicin for 2 days and oral amoxicillin for 7 days (group D). Trained health professionals gave daily injections and the first dose of oral amoxicillin. Our primary outcome was treatment failure by day 8 after enrolment, defined as clinical deterioration, development of a serious adverse event (including death), no improvement by day 4, or not cured by day 8. Independent outcome assessors, who did not know the infants treatment regimen, assessed study outcomes on days 4, 8, 11, and 15. Primary analysis was per protocol. We used a prespecified similarity margin of 5% to assess equivalence between regimens. This study is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12610000286044. FINDINGS In Kenya and Nigeria, we started enrolment on April 4, 2011, and we enrolled the necessary number of young infants aged 7 days or older from Oct 17, 2011, to April 30, 2012. At these sites, we continued to enrol infants younger than 7 days until March 29, 2013. In DR Congo, we started enrolment on Sept 17, 2012, and continued until June 28, 2013. We randomly assigned 3564 young infants to either group A (n=894), group B (n=884), group C (n=896), or group D (n=890). We excluded 200 randomly assigned infants, who did not fulfil the predefined criteria of adherence to treatment and adequate follow-up. In the per-protocol analysis, 828 infants were included in group A, 826 in group B, 862 in group C, and 848 in group D. 67 (8%) infants failed treatment in group A compared with 51 (6%) infants in group B (risk difference -1·9%, 95% CI -4·4 to 0·1), 65 (8%) in group C (-0·6%, -3·1 to 2·0), and 46 (5%) in group D (-2·7%, -5·1 to 0·3). Treatment failure in groups B, C, and D was within the similarity margin compared with group A. During the 15 days after random allocation, 12 (1%) infants died in group A, compared with ten (1%) infants in group B, 20 (2%) infants in group C, and 11 (1%) infants in group D. An infant in group A had a serious adverse event other than death (injection abscess). INTERPRETATION The three simplified regimens were as effective as injectable procaine benzylpenicillin-gentamicin for 7 days on an outpatient basis in young infants with clinical signs of severe infection, without signs of critical illness, and whose caregivers did not accept referral for hospital admission. FUNDING Bill & Melinda Gates Foundation grant to WHO.


The Lancet | 2015

Oral amoxicillin compared with injectable procaine benzylpenicillin plus gentamicin for treatment of neonates and young infants with fast breathing when referral is not possible: a randomised, open-label, equivalence trial

Antoinette Tshefu; Adrien Lokangaka; Serge Ngaima; Cyril Engmann; Fabian Esamai; Peter Gisore; Adejumoke I. Ayede; Adegoke Gbadegesin Falade; Ebunoluwa A. Adejuyigbe; Chineme Henry Anyabolu; Robinson D. Wammanda; Clara Ejembi; William N. Ogala; Lu Gram; Simon Cousens

BACKGROUND WHO recommends referral to hospital for possible serious bacterial infection in young infants aged 0-59 days. We aimed to assess whether oral amoxicillin treatment for fast breathing, in the absence of other signs, is as efficacious as the combination of injectable procaine benzylpenicillin-gentamicin. METHODS In a randomised, open-label, equivalence trial at five sites in DR Congo, Kenya, and Nigeria, community health workers followed up all births in the community, identified unwell young infants, and referred them to study nurses. We randomly assigned infants with fast breathing as a single sign of illness or possible serious bacterial infection, whose parents did not accept referral to hospital, to receive either injectable procaine benzylpenicillin-gentamicin once per day or oral amoxicillin treatment twice per day for 7 days. A person who was off-site generated randomisation lists using computer software. Trained health professionals gave injections, but outcome assessors were masked to group allocations. The primary outcome was treatment failure by day 8 after enrolment, defined as clinical deterioration, development of a serious adverse event including death, persistence of fast breathing on day 4, or recurrence up to day 8. The primary analysis was per protocol and we used a prespecified similarity margin of 5% to assess equivalence between regimens. This study is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12610000286044. FINDINGS From April 4, 2011, to March 29, 2013, we enrolled 2333 infants aged 0-59 days with fast breathing as the only sign of possible serious bacterial infection at the five study sites. We assigned 1170 infants to receive injectable procaine benzylpenicillin-gentamicin and 1163 infants to receive oral amoxicillin. In the per-protocol analysis, from which 137 infants were excluded, we included 1061 (91%) infants who fulfilled predefined criteria of adherence to treatment and adequate follow-up in the injectable procaine benzylpenicillin-gentamicin group and 1145 (98%) infants in the oral amoxicillin group. In the procaine benzylpenicillin-gentamicin group, 234 infants (22%) failed treatment, compared with 221 (19%) infants in the oral amoxicillin group (risk difference -2·6%, 95% CI -6·0 to 0·8). Four infants died within 15 days of follow-up in each group. We detected no drug-related serious adverse events. INTERPRETATION Young infants with fast breathing alone can be effectively treated with oral amoxicillin on an outpatient basis when referral to a hospital is not possible. FUNDING Bill & Melinda Gates Foundation grant to WHO.


Reproductive Health | 2014

Maternal and perinatal health research priorities beyond 2015: an international survey and prioritization exercise.

João Paulo Souza; Mariana Widmer; Ahmet Metin Gülmezoglu; Theresa A Lawrie; Ebunoluwa A. Adejuyigbe; Guillermo Carroli; Caroline A Crowther; Sheena Currie; Therese Dowswell; Justus Hofmeyr; Tina Lavender; Joy E Lawn; Silke Mader; Francisco Eulógio Martinez; Kidza Mugerwa; Zahida Qureshi; Maria Asuncion Silvestre; Hora Soltani; Maria Regina Torloni; Eleni Tsigas; Zoe Vowles; Leopold Ouedraogo; Suzanne Serruya; Jamela Al-Raiby; Narimah Awin; Hiromi Obara; Matthews Mathai; Rajiv Bahl; Jose Martines; Bela Ganatra

BackgroundMaternal mortality has declined by nearly half since 1990, but over a quarter million women still die every year of causes related to pregnancy and childbirth. Maternal-health related targets are falling short of the 2015 Millennium Development Goals and a post-2015 Development Agenda is emerging. In connection with this, setting global research priorities for the next decade is now required.MethodsWe adapted the methods of the Child Health and Nutrition Research Initiative (CHNRI) to identify and set global research priorities for maternal and perinatal health for the period 2015 to 2025. Priority research questions were received from various international stakeholders constituting a large reference group, and consolidated into a final list of research questions by a technical working group. Questions on this list were then scored by the reference working group according to five independent and equally weighted criteria. Normalized research priority scores (NRPS) were calculated, and research priority questions were ranked accordingly.ResultsA list of 190 priority research questions for improving maternal and perinatal health was scored by 140 stakeholders. Most priority research questions (89%) were concerned with the evaluation of implementation and delivery of existing interventions, with research subthemes frequently concerned with training and/or awareness interventions (11%), and access to interventions and/or services (14%). Twenty-one questions (11%) involved the discovery of new interventions or technologies.ConclusionsKey research priorities in maternal and perinatal health were identified. The resulting ranked list of research questions provides a valuable resource for health research investors, researchers and other stakeholders. We are hopeful that this exercise will inform the post-2015 Development Agenda and assist donors, research-policy decision makers and researchers to invest in research that will ultimately make the most significant difference in the lives of mothers and babies.


Pediatric Infectious Disease Journal | 2013

Scientific rationale for study design of community-based simplified antibiotic therapy trials in newborns and young infants with clinically diagnosed severe infections or fast breathing in South Asia and sub-Saharan Africa

Anita K. M. Zaidi; Abdullah H. Baqui; Shamim Qazi; Rajiv Bahl; Samir K. Saha; Adejumoke I. Ayede; Ebunoluwa A. Adejuyigbe; Cyril Engmann; Fabian Esamai; Antoinette Tshefu; Robinson D. Wammanda; Adegoke Gbadegesin Falade; Adetanwa I. Odebiyi; Peter Gisore; Adrien Lokangaka Longombe; William N. Ogala; Shiyam Sundar Tikmani; A. S. M. Nawshad Uddin Ahmed; Steve Wall; Neal Brandes; Daniel E. Roth; Gary L. Darmstadt

Background: Newborns and young infants suffer high rates of infections in South Asia and sub-Saharan Africa. Timely access to appropriate antibiotic therapy is essential for reducing mortality. In an effort to develop community case management guidelines for young infants, 0–59 days old, with clinically diagnosed severe infections, or with fast breathing, 4 trials of simplified antibiotic therapy delivered in primary care clinics (Pakistan, Democratic Republic of Congo, Kenya and Nigeria) or at home (Bangladesh and Nigeria) are being conducted. Methods: This article describes the scientific rationale for these trials, which share major elements of trial design. All the trials are in settings of high neonatal mortality, where hospitalization is not feasible or frequently refused. All use procaine penicillin and gentamicin intramuscular injections for 7 days as reference therapy and compare this to various experimental arms utilizing comparatively simpler combination regimens with fewer injections and oral amoxicillin. Conclusion: The results of these trials will inform World Health Organization policy regarding community case management of young infants with clinical severe infections or with fast breathing.


Journal of Human Lactation | 2008

Infant feeding intentions and practices of HIV-positive mothers in southwestern Nigeria.

Ebunoluwa A. Adejuyigbe; E. O. Orji; Adedeji Onayade; Niyi Makinde; Henry Chineme Anyabolu

It has been shown that infant feeding pattern affects mother-to-child transmission of HIV. This study reports the infant feeding practices of HIV-positive mothers in southwestern Nigeria. J Hum Lact. 24(3):303-310. Este estudio investigó factores que determinan las intenciones de alimentación infantil y las prácticas verdaderas de 104 mujeres embarazadas infectadas con el VIH en el suroeste de Nigeria desde Enero del 2004 a Junio del 2006. Ellas recibieron conserjería como se recomienda en las directrices de alimentación infantil de la OMS y seguimiento mensual durante 6 meses postparto. Entre ellas, 71 (68.3%) y 33 (31.7%) planeaban lactancia materna exclusiva (LME) y alimentación de reemplazo exclusiva (ARE) respectivamente. Las madres con compañeros que sabían que eran VIH positivos, que habían revelado su estado de VIH a sus familiares/ amigos, y que tenían historia de un hijo muerto planearon ARE. De 84 parejas madre-hijo que completaron el estudio, 9 (15.5%) y 13(50%) de aquellas que tenían la intención de LME y ARE respectivamente practicaron alimentación mixta (p = 0.001). Se concluyó que la mayoría de madres infectadas con VIH que recibieron conserjería basada en las recomendaciones de la OMS prefirieron LME. Las madres que habían revelado su estado de VIH, con historia de hijo muerto y con esposo que sabia que era VIH positivo practicaron mas la ARE.


Journal of Antimicrobial Chemotherapy | 2015

Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS

Adeniyi Olagunju; Oluseye O. Bolaji; Alieu Amara; Catriona Waitt; Laura Else; Julius O. Soyinka; Babatunde A. Adeagbo; Ebunoluwa A. Adejuyigbe; Marco Siccardi; David Back; Andrew Owen; Saye Khoo

OBJECTIVES This manuscript describes the development, validation and clinical application of a novel method for the quantification of the antiretroviral drug efavirenz in dried breast milk spots using LC-MS. METHODS Dried breast milk spots were prepared by spotting 30 μL of human breast milk on each circle of Whatman 903 Protein Saver cards. Chromatographic separation was achieved on a reverse-phase C18 column with 1 mM ammonium acetate in water/acetonitrile using a solvent gradient at a flow rate of 400 μL/min and detection was by TSQ Quantum Access triple quadrupole mass spectrometer equipped with a heated electrospray ionization source. The method was applied to characterize the breast milk pharmacokinetic profile of efavirenz in HIV-positive nursing mothers receiving regimens containing 600 mg of efavirenz once daily. RESULTS The assay was validated over the concentration range 50-7500 ng/mL. Accuracy ranged between 95.2% and 102.5% and precision ranged between 1.05% and 9.53%. The average recovery of efavirenz from dried breast milk spots was 106.4% and the matrix effect was 8.14%. Stability of efavirenz in dried breast milk spots and processed samples at room temperature, -40°C and -80°C was demonstrated. In the pharmacokinetic study, the mean (SD) AUC0-24, Cmax and Cmin of efavirenz in breast milk were 59,620 ng·h/mL (17,440), 4527 ng/mL (1767) and 1261 ng/mL (755.9), respectively. The mean (range) milk-to-plasma concentration ratio over the dosing interval was 0.78 (0.57-1.26). CONCLUSIONS The dried breast milk spot method is simple, robust, accurate and precise, and can be used in settings with limited resources.


Pediatric Infectious Disease Journal | 2013

Ongoing trials of simplified antibiotic regimens for the treatment of serious infections in young infants in South Asia and sub-Saharan Africa: implications for policy.

Fabian Esamai; Antoinette Tshefu; Adejumoke I. Ayede; Ebunoluwa A. Adejuyigbe; Robinson D. Wammanda; Abdullah H. Baqui; Anita K. M. Zaidi; Samir K. Saha; Nigel Rollins; Stephen Wall; Neal Brandes; Cyril Engmann; Gary L. Darmstadt; Shamim Qazi; Rajiv Bahl

Background: The current World Health Organization (WHO) recommendation for treatment of severe infection in young infants is hospitalization and parenteral antibiotic therapy. Hospital care is generally not available outside large cities in low- and middle-income countries and even when available is not acceptable or affordable for many families. Previous research in Bangladesh and India demonstrated that treatment outside hospitals may be possible. Research: A set of research studies with common protocols testing simplified antibiotic regimens that can be provided at the lowest-level health-care facility or at home are nearing completion. The studies are large individually randomized controlled trials that are set up in the context of a program, which provides home visits by community health workers to detect serious illness in young infants with assessment and treatment at an outpatient health facility near home. This article summarizes the policy implications of the research studies. Policy Implications: The studies are expected to result in information that would inform WHO guidelines on simple, safe and effective regimens for the treatment of clinical severe infection and pneumonia in newborns and young infants in settings where referral is not possible. The studies will also inform the inputs and process required to establish outpatient treatment of newborn and young infant infections at health facilities near the home. We expect that the information from research and the resulting WHO guidelines will form the basis of policy dialogue by a large number of stakeholders at the country level to implement outpatient treatment of neonatal infections and thereby reduce neonatal and infant mortality resulting from infection.


Pediatric Infectious Disease Journal | 2013

Ensuring Quality in AFRINEST and SATT: Clinical Standardization and Monitoring

Stephen Wall; Corinne I. Mazzeo; Ebunoluwa A. Adejuyigbe; Adejumoke I. Ayede; Rajiv Bahl; Abdullah H. Baqui; William C. Blackwelder; Neal Brandes; Gary L. Darmstadt; Fabian Esamai; Patricia L. Hibberd; Marian Jacobs; Jerome O. Klein; Kasonde Mwinga; Nigel Rollins; Haroon Saloojee; Antoinette Tshefu; Robinson D. Wammanda; Anita K. M. Zaidi; Shamim Qazi

Background: Three randomized open-label clinical trials [Simplified Antibiotic Therapy Trial (SATT) Bangladesh, SATT Pakistan and African Neonatal Sepsis Trial (AFRINEST)] were developed to test the equivalence of simplified antibiotic regimens compared with the standard regimen of 7 days of parenteral antibiotics. These trials were originally conceived and designed separately; subsequently, significant efforts were made to develop and implement a common protocol and approach. Previous articles in this supplement briefly describe the specific quality control methods used in the individual trials; this article presents additional information about the systematic approaches used to minimize threats to validity and ensure quality across the trials. Methods: A critical component of quality control for AFRINEST and SATT was striving to eliminate variation in clinical assessments and decisions regarding eligibility, enrollment and treatment outcomes. Ensuring appropriate and consistent clinical judgment was accomplished through standardized approaches applied across the trials, including training, assessment of clinical skills and refresher training. Standardized monitoring procedures were also applied across the trials, including routine (day-to-day) internal monitoring of performance and adherence to protocols, systematic external monitoring by funding agencies and external monitoring by experienced, independent trial monitors. A group of independent experts (Technical Steering Committee/Technical Advisory Group) provided regular monitoring and technical oversight for the trials. Conclusions: Harmonization of AFRINEST and SATT have helped to ensure consistency and quality of implementation, both internally and across the trials as a whole, thereby minimizing potential threats to the validity of the trials’ results.


Aids Care-psychological and Socio-medical Aspects of Aids\/hiv | 2004

Sociodemographic characteristics of HIV-positive mother-child pairs in Ile-Ife, Nigeria

Ebunoluwa A. Adejuyigbe; O. B. Fasubaa; A. A. Onayade

This study was designed to identify sociodemographic characteristics of HIV-positive mother-child pairs in the southwest of Nigeria. The aim was to identify factors that will be helpful in designing initiatives for preventing mother to child transmission (MTCT) of the virus. It was a hospital-based, case-control study carried out at the Obafemi Awolowo University Teaching Hospital, Ile-Ife, Nigeria from August 2000 to July 2002. Eligible mother-child pairs identified at the paediatric department, who consented to participate in the study, were interviewed using semi-structured questionnaires and screened for HIV seropositivity. Ninety-three (46.7%) of 199 mother-child pairs were HIV-positive. When compared with the 106 HIV-negative mothers, the HIV-positive mothers were younger, unemployed, had earlier sexual exposure, lower education and were married to polygynous spouses. It is recommended that initiatives designed to reduce MTCT of the HIV virus in the southwest of Nigeria should include education and improvement of the economic status of female adolescents; promotion of cultural practices such as virginity until marriage while discouraging polygyny and early marriage. Health education on prevention of HIV infection should target potential mothers and their partners.


Aids Care-psychological and Socio-medical Aspects of Aids\/hiv | 2006

Parental HIV serodiscordance: Implications for the care of the HIV seropositive child in a resource-poor setting

Ebunoluwa A. Adejuyigbe; A. I. Odebiyi

Abstract This prospective study compared the care and support provided for symptomatic HIV seropositive children of HIV serodiscordant parents (only the mother of the child is HIV infected) with children of seroconcordant parents (both parents are HIV infected) during admission and after discharge from a tertiary health institution in southwestern Nigeria. Information was collected from parents of eligible children by semi-structured questionnaires and observation of the children and their parents while on admission and at home. Of the 51 couples who met the study criteria, there were 27 seroconcordant couples and 24 serodiscordant couples. The children from serodiscordant couples were more frequently discharged against medical advice, abandoned, lost to follow-up, cared for by their mothers alone and were not up-to-date with their immunization schedule when compared with children from seroconcordant parents. These were statistically significant (p < 0.05). There was a higher mortality among these children and their mothers (p < 0.05). Paternal reasons for not providing adequate care for the children from serodiscordant parents included fear of being infected, doubt of childs paternity and waste of family resources on a ‘child who is dying’. None of the children from both groups received support from governmental and non-governmental agencies. It is concluded that the care of sick HIV seropositive children of serodiscordant parents poses special challenges for clinicians working in Nigeria where there is no social support system.

Collaboration


Dive into the Ebunoluwa A. Adejuyigbe's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Rajiv Bahl

World Health Organization

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Cyril Engmann

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lu Gram

University of London

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge